AMYLOID CARDIOMYOPATHY: DIAGNOSIS AND TREATMENT

The review presents current data on heart disease in systemic amyloidosis. The article discusses variants of amyloi-dosis with common heart disease: AL-, ATTRwt- and ATTRv amyloidoses. Clinical signs of amyloid cardiomyopathy and extracardiac manifestations that allow one to suggest amyloidosis are described. Methods for diagnosing amyloid cardiomyopathy are presented.
Echocardiographic diagnostic characters include increased thickness of the left ventricular wall, atrioventricular valve, right ventricular wall, thickening of the interatrial septum, and also diastolic dysfunction, and decreased global longi-tudinal strain with relative preservation of apical longitudinal strain.
Magnetic resonance imaging reveals signs specific for amyloidosis: increased extracellular volume and diffuse suben-docardial or transmural delayed enhancement after gadolinium administration.
Scintigraphy using technetium-99m labeled compounds can confirm the diagnosis of ATTR cardiomyopathy. The diag-nosis of ATTR cardiomyopathy is only possible in combination with blood and urine tests to exclude the presence of a monoclonal protein. Screening for monoclonal protein includes three laboratory tests: determination of free light chains in blood serum, electrophoresis of serum protein and urine protein with immunofixation.
Indications for myocardial biopsy and the role of extracardiac tissue biopsy are discussed. Endomyocardial biopsy should be performed: a) in case of strong clinical suggestion of cardiac amyloidosis in a patient with monoclonal pro-tein; b) in case of strong clinical suggestion of cardiac amyloidosis, despite negative or equivocal scintigraphy result; c) if cardiac scintigraphy is not available.
The possibilities of pathogenetic therapy for ATTR- and AL amyloidosis, aimed at stopping or slowing amyloid deposi-tion in the heart, and symptomatic treatment are discussed.

1. Spanggaard MB, Hansen CT, Maiborg M, et al. Amyloidosis is a disease with many faces. Ugeskr. Laeger. 2023;185:V08220479

2. Benson MD, Buxbaum JN,Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2018;25:215–219. DOI: 10.1080/13506129.2018.1549825

3. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2020;27:217–222. DOI: 10.1080/13506129.2020.1835263

4. Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 2022;29:213–219. DOI: 10.1080/13506129.2022.2147636

5. Kittleson MM, Frederick L Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076-1126. DOI: 10.1016/j.jacc.2022.11.022

6. Halatchev IG, Zheng J, Ou J. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. J Thorac Dis. 2018;10(3):2034-2045. DOI: 10.21037/jtd.2018.03.134

7. Bajwa F, O’Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail. Rev. 2022;27:1471–1484. DOI: 10.1007/s10741-021-10162-1

8. Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271-2280. DOI: 10.1182/blood.2019000834

9. Oghina S, Delbarre MA, Poullot E, et al. Cardiac amyloidosis: State of art in 2022. Rev. Med. Interne. 2022;43:537–544. DOI: 10.1016/j.revmed.2022.04.036

10. Manganelli F, Fabrizi GM, Luigetti M, et al. Hereditary transthyretin amyloidosis overview. Neurol. Sci. 2022;43:595–604. DOI: 10.1007/s10072-020-04889-2

11. Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3-9. DOI: 10.1080/13506129.2018.1556156

12. Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2:1046–1053. DOI: 10.1182/bloodadvances.2018016402

13. Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38. DOI: 10.1038/s41572-018-0034-3

14. Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987–2019. N Engl J Med. 2020;382:1567–1568. DOI: 10.1056/NEJMc1917321

15. AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1267–1274. DOI: 10.1001/jamacardio.2021.3070

16. Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic/Latino ancestry. JAMA. 2019;322:2191–2202. DOI: 10.1001/jama.2019.17935

17. Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int. J. Cardiol. 2020;300:191–195. DOI: 10.1016/j.ijcard.2019.07.051

18. Scully PR, Treibel TA, Patel KP, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41:2759–2767. DOI: 10.1093/eurheartj/ehaa170

19. Полякова АА, Семернин ЕН, Ситникова МЮ, и др. Транстиретиновый амилоидоз в когорте пациентов с хронической сердечной недостаточностью старческого возраста и долгожителей. Кардиология. 2018;58(S2):12–18. [Poliakova AA, Semernin EN, Sitnikova MYu. et al. Transthyretin amyloidosis in a cohort of old and very old patients with chronic heart failure. Kardiologiia. 2018:58(S2):12–18 (In Russian)]. DOI: 10.18087/cardio.2390

20. Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol. 2023 May 28;20(5):361-375. DOI: 10.26599/1671-5411.2023.05.006

21. Резник ЕВ, Нгуен ТЛ, Степанова ЕА, и др. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020; 10(6): 430-457. [Reznik E.V., Nguyen T.L., Stepanova E.A. et al. Cardiac Amyloidosis: Internist and Cardiologist Insight. The Russian Archives of Internal Medicine. 2020; 10(6): 430-457 (In Russian)]. DOI: 10.20514/2226-6704-2020-10-6-430-457

22. Patel KS, Hawkins PN. Cardiac amyloidosis: Where are we today? J Intern Med. 2015;278(2):126–144. DOI: 10.1111/joim.12383

23. Belfeki N, Ghriss N, Monchi M, Moini C. State of the Art of cardiac amyloidosis. Biomedicines. 2023;11:1045. DOI: 10.3390/biomedicines11041045

24. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. J Am Coll Cardiol HF. 2019;7:709–716. DOI: 10.1016/j.jchf.2019.04.010

25. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7–e22. DOI: 10.1161/CIR.0000000000000792

26. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554–1568. DOI: 10.1093/eurheartj/ehab072

27. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the art review. J Am Coll Cardiol. 2019;73:2872–2891. DOI: 10.1016/j.jacc.2019.04.003

28. McVeigh T, Tennyson C. Understanding and recognizing cardiac amyloidosis. J Am Acad Physician Assist. 2020;33:16–20. DOI: 10.1097/01.JAA.0000697236.11386.3a

29. Versteylen MO, Brons M, Teske AJ, Oerlemans MIFJ. Restrictive atrial dysfunction in cardiac amyloidosis: differences between immunoglobulin light chain and transthyretin cardiac amyloidosis patients. Biomedicines. 2022;10:1768. DOI: 10.3390/biomedicines10081768

30. Mints YY, Doros G, Berk JL, et al. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 2018;5:772–779. DOI: 10.1002/ehf2.12308

31. Donnellan E, Wazni OM, Hanna M, et al. Atrial fibrillation in transthyretin cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6:1118–1127. DOI: 10.1016/j.jacep.2020.04.019

32. Gosciniak P, Baron T, Milczarek S, et al. Updates for the diagnosis and management of cardiac amyloidosis. Adv Clin Exp Med. 2022;31:175–185. DOI: 10.17219/acem/142252

33. Sperry B.W., Reyes B.A., Ikram A. et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72:2040–50. DOI: 10.1016/j.jacc.2018.07.092

34. Milandri A., Farioli A., Gagliardi C. et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020;22:507–515. DOI: 10.1002/ejhf.1742

35. Eldhagen P, Berg S, Lund LH, et al. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med. 2021;289(6):895-905. DOI: 10.1111/joim.13222

36. Geller HI, Singh A, Alexander KM, et al. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA. 2017;318:962–963. DOI: 10.1001/jama.2017.9236

37. Hoffman JE, Dempsey NG, Sanchorawala V. Systemic amyloidosis caused by monoclonal immunoglobulins: soft tissue and vascular involvement. Hematol Oncol Clin North Am. 2020;34:1099–1113. DOI: 10.1016/j.hoc.2020.08.004

38. Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice. 2020;21:198. DOI: 10.1186/s12875-020-01252-4

39. Nativi-Nicolau JN, Karam C, Khella S, et al. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785-793. DOI: 10.1007/s10741-021-10080-2

40. Slivnick JA, Wallner AL, Vallakati A, et al. Indexed left ventricular mass to QRS voltage ratio is associated with heart failure hospitalizations in patients with cardiac amyloidosis. Int J Cardiovasc Imaging. 2021;37(3):1043-1051. DOI: 10.1007/s10554-020-02059-1

41. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065–2123. DOI: 10.1007/s12350-019-01760-6

42. Boldrini M, Cappelli F, Chacko L, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13:909–920 DOI: 10.1016/j.jcmg.2019.10.011

43. Ferkh A, Tjahjadi C, Stefani L, et al. Cardiac “hypertrophy”phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography. Front Cardiovasc Med. 2023;10:1183485. DOI: 10.3389/fcvm.2023.1183485

44. Brownrigg J, Lorenzini M, Lumley M, et al. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 2019;6:1041–1051. DOI: 10.1002/ehf2.12511

45. Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. J Am Coll Cardiol Img. 2020;13:1368–1383. DOI: 10.1016/j.jcmg.2019.07.015

46. Knight DS, Zumbo G, Barcella W, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC: Cardiovascular Imaging. 2019;12(5):823-833. DOI:10.1016/j.jcmg.2018.02.016

47. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–1084. DOI: 10.1016/j.jacc.2005.05.073

48. Hanna M, Ruberg FL, Maurer MS, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020;75:2851– 2862. DOI: 10.1016/j.jacc.2020.04.022

49. Quarta CC, Zheng J, Hutt D, et al. 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2021;22:1304–1311. DOI: 10.1093/ehjci/jeab095

50. Sidiqi MH, McPhail ED, Theis JD, et al. Two types of amyloidosis presenting in a single patient: a case series. Blood Cancer J. 2019;9:30. DOI: 10.1038/s41408-019-0193-9

51. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075. DOI: 10.1161/CIRCHEARTFAILURE.119.006075

52. Antukh D, Shchekochikhin D, Rosina T, et al. Scintigraphy false-positive results for cardiac amyloidosis in a patient with Danon disease. Clin Case Rep. 2021;9:e04652. DOI: 10.1002/ccr3.4652

53. Chimenti C, Alfarano M, Maestrini V, et al. False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy. ESC Heart Fail. 2021;8:3387–3391. DOI: 10.1002/ehf2.13339

54. Witteles RM, Liedtke M. Avoiding catastrophe: understanding free light chain testing in the evaluation of ATTR amyloidosis. Circ Heart Fail. 2021;14:e008225. DOI: 10.1161/CIRCHEARTFAILURE.120.008225

55. Long TE, Indridason OS, Palsson R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12:133. DOI: 10.1038/s41408-022-00732-3

56. Muchtar E, Gertz MA, Kyle RA, et al. A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc. 2019;94:472–483. DOI: 10.1016/j.mayocp.2018.08.006

57. Лысенко (Козловская) Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клин фармакол тер. 2020;29(1):13-24. [Lysenko (Kozlovskaya) LV, Rameev VV, MoiseevS, et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya. 2020;29(1):13-24 (In Russian)]. DOI 10.32756/0869-5490-2020-1-13-24.

58. Schmidt M, Wiese S, Adak V, et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat Commun. 2019;10:5008. DOI:10.1038/s41467-019-13038-z

59. Wisniowski B, Wechalekar A. Confirming the diagnosis of amyloidosis. Acta Haematol. 2020;143:312–321. DOI: 10.1159/000508022

60. Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: Red flags from clinical, laboratory and imaging findings. Eur. J. Prev. Cardiol. 2020, 27, 1806–1815. DOI: 10.1177/2047487319877708

61. Sperry BW, Hanna M, Shah SJ, et al. Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT. JACC Heart Fail. 2021, 9, 795–802. DOI: 10.1016/j.jchf.2021.06.007

62. Zampieri M, Argirò A, Allinovi M, et al. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern. Emerg Med. 2022;17:1243–1245. DOI: 10.1007/s11739-022-02944-8

63. Griffin J.M, Rosenthal JL, Grodin JL, et al. ATTR Amyloidosis: Current and emerging management strategies: JACC: CardioOncology State-of-the-Art Review. JACC Cardio Oncol. 2021;3:488–505. DOI: 10.1016/j.jaccao.2021.06.006

64. King P, Kates AM. Management of cardiac symptoms in amyloidosis. Am J Med. 2022;135 Suppl 1:S9–S12. DOI: 10.1016/j.amjmed.2022.02.005

65. Di Lisi D, Di Caccamo L, Damerino G, et al. Effectiveness and safety of oral anticoagulants in cardiac amyloidosis: lights and shadows. Curr Probl Cardiol. 2022; 48(8):101188. DOI: 10.1016/j.cpcardiol.2022.101188

66. Bukhari S, Khan SZ, Bashir Z. Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: a review. J Card Fail. 2023;29:76–86. DOI: 10.1016/j.cardfail.2022.08.008

67. Katja Zeppenfeld K, Hansen JT, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;43:3997–4126. DOI: 10.1093/eurheartj/ehac262

68. Kusumoto, F.M.; Schoenfeld, M.H.; Barrett, C.; Edgerton, J.R.; Ellenbogen, K.A.; Gold, M.R.; Goldschlager, N.F.; Hamilton, R.M.; Joglar, J.A.; Kim, R.J.; et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2019, 140, e382–e482

69. Nitsche C.; Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77:128–139. DOI: 10.1016/j.jacc.2020.11.006

70. Palma J-A, Gonzalez-Duarte A, Kaufmann H. Orthostatic hypotension in hereditary transthyretin amyloidosis: Epidemiology, diagnosis and management. Clin Auton Res. 2019;29:33–44. DOI: 10.1007/s10286-019-00623-x

71. Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc. 2017;6:e006848. DOI: 10.1161/JAHA.117.006848